Search Articles
SAN FRANCISCO — Medivation shareholders say in a federal class action that its directors are selling the company too cheaply through an unfair process to Pfizer, for $81.50 a share, or $14 billion.
Categories /
Uncategorized
Subscribe to our free newsletters
Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.